Moreover, Regorafenib has shown direct effects on AD pathology by reducing Aβ plaque accumulation, decreasing tau phosphorylation, and enhancing dendritic spine density in 5xFAD mice. The gene discussed is MAPT; the disease is Alzheimer disease.